HK1046708A1 - 使用atp結合盒式蛋白質輸送器增加膽固醇溢出和提高hdl水平的成分與方法 - Google Patents

使用atp結合盒式蛋白質輸送器增加膽固醇溢出和提高hdl水平的成分與方法

Info

Publication number
HK1046708A1
HK1046708A1 HK02108234.7A HK02108234A HK1046708A1 HK 1046708 A1 HK1046708 A1 HK 1046708A1 HK 02108234 A HK02108234 A HK 02108234A HK 1046708 A1 HK1046708 A1 HK 1046708A1
Authority
HK
Hong Kong
Prior art keywords
regulation
transporter protein
binding cassette
cassette transporter
abc1
Prior art date
Application number
HK02108234.7A
Other languages
English (en)
Inventor
M Lawn Richard
Wade David
Garvin Michael
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of HK1046708A1 publication Critical patent/HK1046708A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
HK02108234.7A 1999-06-18 2002-11-13 使用atp結合盒式蛋白質輸送器增加膽固醇溢出和提高hdl水平的成分與方法 HK1046708A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14026499P 1999-06-18 1999-06-18
US15387299P 1999-09-14 1999-09-14
US16657399P 1999-11-19 1999-11-19
PCT/US2000/016765 WO2000078972A2 (en) 1999-06-18 2000-06-16 Regulation with binding cassette transporter protein abc1

Publications (1)

Publication Number Publication Date
HK1046708A1 true HK1046708A1 (zh) 2003-01-24

Family

ID=27385472

Family Applications (2)

Application Number Title Priority Date Filing Date
HK02107131.3A HK1046427A1 (zh) 1999-06-18 2002-09-26 使用atp結合盒式蛋白質輸送器增加膽固醇溢出和提高hdl水平的成分與方法
HK02108234.7A HK1046708A1 (zh) 1999-06-18 2002-11-13 使用atp結合盒式蛋白質輸送器增加膽固醇溢出和提高hdl水平的成分與方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK02107131.3A HK1046427A1 (zh) 1999-06-18 2002-09-26 使用atp結合盒式蛋白質輸送器增加膽固醇溢出和提高hdl水平的成分與方法

Country Status (19)

Country Link
EP (2) EP1218515B1 (zh)
JP (4) JP2003508031A (zh)
KR (2) KR20020012612A (zh)
CN (2) CN1379817A (zh)
AR (2) AR024391A1 (zh)
AT (1) ATE422545T1 (zh)
AU (3) AU777461B2 (zh)
BR (2) BR0011753A (zh)
CA (2) CA2375787C (zh)
DE (1) DE60041545D1 (zh)
HK (2) HK1046427A1 (zh)
IL (2) IL147022A0 (zh)
MX (2) MXPA01013174A (zh)
NO (2) NO20016121L (zh)
NZ (3) NZ529785A (zh)
SG (2) SG121853A1 (zh)
TR (2) TR200200440T2 (zh)
TW (2) TWI304737B (zh)
WO (2) WO2000078972A2 (zh)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367955C (en) 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
EP1854880A1 (en) * 1999-03-15 2007-11-14 University of British Columbia Methods and reagents for modulating cholesterol levels
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
WO2001015676A2 (en) * 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
US6555323B2 (en) * 2000-02-08 2003-04-29 Pfizer Inc. Assay for ABCA1
EP1280911A2 (en) 2000-05-02 2003-02-05 Aventis Pharma S.A. Regulatory nucleic acid sequences of the ABC1 gene
EP1203588A1 (en) * 2000-11-06 2002-05-08 Bayer Ag Sterol-independent regulation of ABC1 promoter via oncostatinM
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
AU2002317093A1 (en) * 2001-07-03 2003-01-21 University Of British Columbia Screening processes for agents modulating cholesterol levels
JPWO2003033023A1 (ja) * 2001-10-12 2005-02-03 グレラン製薬株式会社 低ｈｄｌ血症改善剤
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003060078A2 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US7265131B2 (en) 2002-12-20 2007-09-04 Exelixis, Inc. Isoquinolinone derivatives and their use as therapeutic agents
BRPI0412262A (pt) 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
WO2005116057A1 (en) * 2004-05-27 2005-12-08 Baker Medical Research Institute Monoclonal antibody against abca1
DK1888640T3 (da) 2005-05-18 2012-06-18 Ablynx Nv Forbedrede nanobodies mod tumornekrosefaktor-alfa
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
US8703805B2 (en) 2005-06-27 2014-04-22 Exelixis Patent Company Llc Modulators of LXR
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
EP2070919B1 (en) 2006-11-24 2012-10-10 Hykes Laboratories LLC Spiroquinone compound and pharmaceutical composition
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
WO2009109635A2 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
ES2610622T3 (es) * 2009-03-31 2017-04-28 The General Hospital Corporation Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol
EP2417163B1 (en) 2009-04-10 2019-02-27 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
MX2011012559A (es) 2009-05-28 2012-06-08 Exelixis Patent Co Llc Moduladores de lxr.
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
MX343085B (es) 2010-11-08 2016-10-24 Novartis Ag Polipeptidos que se enlazan a cxcr2.
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
US9101745B2 (en) * 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
WO2014144037A1 (en) 2013-03-15 2014-09-18 Bristol-Myers Squibb Company Lxr modulators
JP6456909B2 (ja) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
GB201315136D0 (en) * 2013-08-23 2013-10-09 Univ Glasgow Cholesterol modulation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2017089618A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018091606A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
TWI826376B (zh) 2017-06-02 2023-12-21 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
TWI802576B (zh) 2017-06-02 2023-05-21 德商馬克專利公司 與ａｄａｍｔｓ結合之免疫球蛋白
EP3630178A1 (en) 2017-06-02 2020-04-08 Merck Patent GmbH Mmp13 binding immunoglobulins
TWI811220B (zh) 2017-06-02 2023-08-11 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
CN115433733A (zh) 2021-06-04 2022-12-06 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1280911A2 (en) * 2000-05-02 2003-02-05 Aventis Pharma S.A. Regulatory nucleic acid sequences of the ABC1 gene

Also Published As

Publication number Publication date
JP2003508031A (ja) 2003-03-04
WO2000078972A8 (en) 2001-06-21
AR024391A1 (es) 2002-10-02
EP1218515B1 (en) 2009-02-11
CN1434865A (zh) 2003-08-06
BR0011696A (pt) 2002-04-30
CA2375781A1 (en) 2000-12-28
WO2000078971A2 (en) 2000-12-28
CA2375787C (en) 2007-03-27
CN100513570C (zh) 2009-07-15
NO20016121L (no) 2002-02-12
TWI304737B (en) 2009-01-01
EP1218515A2 (en) 2002-07-03
BR0011753A (pt) 2002-04-30
NO20016114D0 (no) 2001-12-14
KR20020012612A (ko) 2002-02-16
SG121852A1 (en) 2006-05-26
NZ516061A (en) 2004-04-30
NO20016114L (no) 2002-02-12
WO2000078972A2 (en) 2000-12-28
CN1379817A (zh) 2002-11-13
JP2006137750A (ja) 2006-06-01
TR200200441T2 (tr) 2002-11-21
MXPA01013174A (es) 2002-06-04
HK1046427A1 (zh) 2003-01-10
AU5743400A (en) 2001-01-09
IL147021A0 (en) 2002-08-14
KR100476519B1 (ko) 2005-03-17
AR024576A1 (es) 2002-10-16
TWI259205B (en) 2006-08-01
CA2375787A1 (en) 2000-12-28
AU777461B2 (en) 2004-10-14
IL147022A0 (en) 2002-08-14
AU2005200171A1 (en) 2005-02-10
KR20020012281A (ko) 2002-02-15
ATE422545T1 (de) 2009-02-15
NZ531401A (en) 2005-08-26
JP4277956B2 (ja) 2009-06-10
WO2000078972A9 (en) 2002-07-18
TR200200440T2 (tr) 2002-09-23
AU5746700A (en) 2001-01-09
SG121853A1 (en) 2006-05-26
TW200626176A (en) 2006-08-01
WO2000078971A3 (en) 2002-01-17
WO2000078972A3 (en) 2002-05-02
JP2003506097A (ja) 2003-02-18
JP2005112859A (ja) 2005-04-28
NO20016121D0 (no) 2001-12-14
EP1190065A2 (en) 2002-03-27
DE60041545D1 (de) 2009-03-26
NZ529785A (en) 2005-09-30
MXPA01013175A (es) 2002-06-04

Similar Documents

Publication Publication Date Title
HK1046708A1 (zh) 使用atp結合盒式蛋白質輸送器增加膽固醇溢出和提高hdl水平的成分與方法
IL146451A0 (en) C-terminal protein tagging
IL142170A0 (en) Pesticidal proteins
EP1150942A4 (en) IMPROVED PROTEIN BINDING COMPOUNDS
GB9921125D0 (en) Proteins
AU6223700A (en) Gtp-binding associated proteins
EP1295939A4 (en) INSULIN SIMILAR GROWTH FACTOR BINDING PROTEIN
GB9928950D0 (en) Binding protein
EP0996626A4 (en) Glycine-TRANSPORTER
GB2352839B (en) Assembly line transporter control system
GB9819998D0 (en) Immunoglobulin binding protein
AU5058800A (en) Continuous transporter
IL150134A0 (en) Apoptin-associating protein
EP1146053A4 (en) PROTEIN MEG-4
EP1209231A4 (en) MEG-1 PROTEIN
EG22315A (en) Binding element
GB9909578D0 (en) Immunoglobulin binding protein
AU4487500A (en) Novel human transporter proteins
GB2351604B (en) Magnetoresistive element
GB9909422D0 (en) Transporter
AU139951S (en) Grain transporter
GB9924060D0 (en) VIP54 protein
EP1188828A4 (en) REG-BINDING PROTEIN
GB2367636B (en) Assembly line transporter control system
GB9616764D0 (en) Reel transporter